<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04638959</url>
  </required_header>
  <id_info>
    <org_study_id>KY[2019]130</org_study_id>
    <nct_id>NCT04638959</nct_id>
  </id_info>
  <brief_title>Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GC</brief_title>
  <official_title>Faecal Bacteria Detection in Early Screening and Diagnosis of Gastric Cancer: a Large-scale Multi-center Case-control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jing'an District Central Hospital of Shanghai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seventh Medical Center of PLA Army General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongshan Hospital Xiamen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this clinical trial, we aim to explore the synergistic alteration of specific bacteria&#xD;
      both in gastric mucosas and feces of gastric cancer patients for the method of non-invasive&#xD;
      and cost-effective faecal marker detection. We aim to select and validate specific microbes&#xD;
      as noninvasive, accurate, simple, sensitive and highly-accepted biomarkers that might assist&#xD;
      to screen and diagnose gastric cancer, especially early gastric cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We conducted a large-scale multi-centre retrospective case-control study. Approximately a&#xD;
      total of 1080 volunteers aging 40-75 in three independent cohorts, discovery cohort,&#xD;
      validation cohort 1, validation cohort 2, will be recruited from 10 hospitals throughout&#xD;
      China. Among them, 530 subjects in both discovery cohort and validation cohort 1 were from&#xD;
      Shanghai Jiao Tong University School of Medicine Renji Hospital from August to December in&#xD;
      2018. Around 550 participants will be enrolled in validation cohort 2 from nine hospitals in&#xD;
      China.Each cohort recruits both patients diagnosed with GC (GC group) and gender, age and&#xD;
      body mass index (BMI)-matched healthy-control (HC) individuals diagnosed with chronic&#xD;
      gastritis by histopathology). Individuals enrolled were either asymptomatic undergoing upper&#xD;
      GI endoscopy screening or went to GI clinic with digestive symptoms. Subjects in HC group are&#xD;
      conducted colonoscopy within 0.5 year before or after upper endoscopy. We collect gastric&#xD;
      tissue biopsies and stool samples from gastric cancer patients and healthy-controls. First in&#xD;
      the discovery cohort, which will recruit 20 subjects, 13 pairs of both cancerous &amp;&#xD;
      noncancerous gastric tissues and pre-operation feces in GC group will be collected. 7&#xD;
      subjects provide their paired mucosal biopsies and stools in HC group before examination. 16S&#xD;
      ribosomal RNA gene sequencing will be used to select the synergistically differential&#xD;
      bacteria species as well as find out microbial compositional distinction and diversity from&#xD;
      both tissue and stool samples between GC and HC group. Second, the validation cohort 1&#xD;
      recruiting a total of 510 subjects (294 GC patients and 216 HC individuals), 217&#xD;
      pre-operation faecal specimens and 141 fresh tissues (cancerous &amp; noncancerous tissues) from&#xD;
      GC group, and 127 faecal samples and 124 gastric biopsies will be collected. Quantitative PCR&#xD;
      (qPCR) will be used to validate the high-throughput sequencing results in discovery cohort in&#xD;
      a single center. Among them, 35 objects in HC group and 64 patients in GC group will provide&#xD;
      their paired tissues and feces. Third, in validation cohort 2, we are going to enroll&#xD;
      volunteers from multiple geographic locations to confirm our results. 550 stool samples will&#xD;
      be collected to further validate the accuracy, sensitivity and specificity of the cut-off&#xD;
      value analyzed from validation cohort 1. All results of laboratory tests including tumor&#xD;
      markers CEA, CA199,CA724 were obtained from the electronic query system. The GC stages will&#xD;
      be assessed by the TNM system according to AJCC Version 4.2017 based on surgical records,&#xD;
      histopathology and radiographic images (eg. PET-CT, abdominal enhanced CT). All subjects will&#xD;
      sign up informed consent form before sample collection. The protocol of present study was&#xD;
      approved by Ethics Review Committee of all participating hospitals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>differences in abundance of gut microbiota</measure>
    <time_frame>1 year</time_frame>
    <description>differences in abundance of gut microbiota for participants with different clinical outcomes confirmed by qPCR(quantitive polymerase chain reaction)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>evidence of gastric carcinoma</measure>
    <time_frame>1 year</time_frame>
    <description>Different outcomes for gastric carcinoma confirmed by endoscopy and pathology</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Basic information of patients with different clinical outcomes</measure>
    <time_frame>1 year</time_frame>
    <description>Basic information of patients with different clinical outcomes by a questionnaire</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Non-invasive and Sensitive Faecal Bacterial Markers for Early Screening and Diagnosis of Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>GC</arm_group_label>
    <description>patients diagnosed with GC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HC</arm_group_label>
    <description>patients diagnosed with chronic gastritis by histopathology</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>collect gastric tissue and stool samples</intervention_name>
    <description>collect gastric tissue and stool samples</description>
    <arm_group_label>GC</arm_group_label>
    <arm_group_label>HC</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      gastric cancer tissues gastric mucosa stools&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants are required to complete a structured questionnaire for assessment of&#xD;
        inclusion requirement.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1）Age between 40 and 75;&#xD;
&#xD;
          -  2）Subjects in GC group are pathologically diagnosed as gastric cancer prior to any&#xD;
             treatment such as surgery, endoscopic resection, chemotherapy, radiotherapy,&#xD;
             immunotherapy, traditional Chinese medicine therapy, etc. The results of their&#xD;
             preoperative abdominal enhanced CT or PET-CT indicated no obvious bowel abnormalities&#xD;
             (inflammation, polyps, ulcers, tumors, erosions, melanosis, etc.);&#xD;
&#xD;
          -  3) Subjects in HC group are diagnosed with chronic gastritis by endoscopy and&#xD;
             pathology. without ulcers, polyps, tumors, severe erosions or bile reflux, and no&#xD;
             obvious abnormal findings (inflammation, polyps, ulcers, tumors, erosions, melanosis,&#xD;
             etc.) by colonoscopy within half a year;&#xD;
&#xD;
          -  4) Subjects are willing to cooperate with this research and provide stool/mucosa&#xD;
             samples as required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) with severe systemic infection, nasopharyngeal/oral cavity inflammation&#xD;
             (periodontitis, gingivitis, tonsillitis, etc.), respiratory tract infection, soft&#xD;
             tissue or skin infection, abscess or endocarditis within 3 months prior to&#xD;
             recruitment;&#xD;
&#xD;
          -  2）prior medication history of the following medicine within 3 months: nonsteroidal&#xD;
             anti-inflammatory drugs (NSAIDs), immunosuppressor, antibiotics, probiotics, hormones&#xD;
             or immune-suppressants at least 1 week;&#xD;
&#xD;
          -  3）prior medication history of proton-pump inhibitors or H2 receptor inhibitors for&#xD;
             over 2 months within 1 year;&#xD;
&#xD;
          -  4) with a history of H.pylori eradication therapy within 1 year;&#xD;
&#xD;
          -  5) with severe constipation, diarrhea or defecation habits changes within 3 months;&#xD;
&#xD;
          -  6) personal history of cancer, organ transplantation, parasites infection or other&#xD;
             severe digestive system diseases (inflammatory bowel disease, liver cirrhosis, etc.);&#xD;
&#xD;
          -  7) with uncontrolled digestive bleeding, obstruction, perforation and any trauma or&#xD;
             surgery within 3 months;&#xD;
&#xD;
          -  8) with uncontrolled chronic metabolic or endocrine disorders, e.g. hypertension,&#xD;
             diabetes, hyperlipidemia, hyperuricemia, etc.&#xD;
&#xD;
          -  9) on a vegetarian diet or with great changes of eating habits within 3 months;&#xD;
&#xD;
          -  10) refusal of participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Gastroenterology, the Seventh Medical Center of PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian-Qiu Sheng</last_name>
      <phone>13601187561</phone>
      <email>jianqiu@263.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, Zhongshan Hospital, Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian-Lin Ren</last_name>
      <phone>13606910859</phone>
      <email>jianlin.ren@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, Nanfang Hospital, Southern Medical Univerisity</name>
      <address>
        <city>Guangdong</city>
        <state>Guangzhou</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Si-De Liu</last_name>
      <phone>139022122459</phone>
      <email>liuside@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Gastroenterology and Hepatology, The Affiliated DrumTower of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiao-Ping Zou</last_name>
      <phone>13770771661</phone>
      <email>zouxiaoping795@hoymail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Gastroenterology and Hepatology, Ren-Ji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai Institute of Digestive Disease; Key Laboratory of Gastroenterology &amp; Hepatology, Ministry of Health</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bang-Mao Wang</last_name>
      <phone>13602007150</phone>
      <email>gi.tmuh@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jing'an District Central Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Wang</last_name>
      <phone>13816537860</phone>
      <email>wanghongjzx@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei-Fen Xie</last_name>
      <phone>13701682806</phone>
      <email>weifenxie@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang-Jun Meng</last_name>
      <phone>13816170604</phone>
      <email>xiangjunmeng@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun-Wei Sun</last_name>
      <phone>13917759901</phone>
      <email>sun_yunwei@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jing-yuan Fang, MD, Ph. D</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>faecal bacterial marker</keyword>
  <keyword>early screening and diagnosis</keyword>
  <keyword>gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

